Physician profile
William R King
NPI 1376603712
$6,942.09
in general payments reported to CMS, 2019-2025
58 companies · $951 in 2025
The $951 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $884 · 2021: $759 · 2022: $897 · 2023: $1,064 · 2024: $802 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $512.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $469.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $441.87 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Glaxosmithkline, LLC. | $440.43 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $428.13 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $360.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.76 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $306.09 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $290.36 | 2019-2023 | |
| Astellas Pharma US INC | $276.42 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $270.50 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $243.25 | 2019-2025 | |
| Amarin Pharma, INC. | $230.25 | 2019-2020 | |
| Abbvie INC. | $183.94 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $129.62 | 2021-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.